



## COMy Online 2020 Scientific Program

Day 1: Saturday October 3, 2020 – All time CET	
15:30-17:00	<b>Session 1: Smoldering myeloma: what's next?</b>
	<b>Welcome address by congress Co-Chairs</b>
	How to define high risk smoldering myeloma <b>Irene Ghobrial, USA</b>
	How to treat high risk smoldering myeloma <b>Maria Victoria Mateos, Spain</b>
	Round table discussion <b>Irene Ghobrial, USA, Maria Victoria Mateos, Spain, S. Vincent Rajkumar, USA, Mario Boccadoro, Italy</b>
17:00-18:30	<b>Session 2: Therapy of transplant eligible patients</b>
	Novel induction regimens <b>Philippe Moreau, France</b>
	Maintenance therapy <b>Graham Jackson, UK</b>
	Round table discussion <b>Philippe Moreau, France, Graham Jackson, UK, Paul Richardson, USA, Francesca Gay, Italy</b>
18:30-19:30	<b>Session 3: Plenary lecture</b>
	Role and perspectives of MRD in myeloma <b>Jesus San Miguel, Spain</b>
	Round table discussion <b>Jesus San Miguel, Spain, Herve Avet-Loiseau, France, Bruno Paiva, Spain, Kwee Yong, UK</b>
19:30-20:30	<b>Industry sponsored symposium (GSK)</b>

Day 2: Sunday October 4, 2020 – All time CET	
09:00-10:30	<b>Session 4: Therapy of transplant ineligible patients</b>
	Frailty assessment <b>Sonja Zweegman, The Netherland</b>
	Novel regimens in elderly patients <b>Thierry Facon, France</b>
	Round table discussion



	<p><b>Sonja Zweegman</b>, The Netherland, <b>Thierry Facon</b>, France, <b>Alessandra Larocca</b>, Italy, <b>Maria Victoria Mateos</b>, Spain</p>
<b>10:30-12:00</b>	<p><b>Session 5: Selected oral communications</b></p>
	<p>UPDATED PHASE 1B RESULTS FROM CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-4528 CAR-T CELL THERAPY IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)  <b>Presenter: Andrzej Jakubowiak, USA</b></p> <p>DREAMM-2: BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY/INTOLERANT TO ANTI-CD38 MAB, INCLUDING SUBGROUPS WITH RENAL IMPAIRMENT (RI) AND HIGH-RISK (HR) CYTOGENETICS  <b>Presenter: Lonial Sagar, USA</b></p> <p>DREAMM-5: PLATFORM TRIAL EVALUATING BELANTAMAB MAFODOTIN (A BCMA-DIRECTED IMMUNO-CONJUGATE) IN COMBINATION WITH NOVEL AGENTS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)  <b>Presenter: Ira Gupta, USA</b></p> <p>FINAL ANALYSIS OF A PHASE I-b STUDY OF ISATUXIMAB COMBINED WITH CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): (NCT-02332850)  <b>Presenter: Tom Martin, USA</b></p> <p>OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE REMAIN COMPARABLE TO THE OUTCOMES REPORTED IN THE PHASE 3 TOURMALINE-MM1 STUDY  <b>Presenter: Xavier Leleu, France</b></p> <p>HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO POMALIDOMIDE AND/OR AN ANTI-CD38 MONOCLONAL ANTIBODY (MAB) – FINAL PRIMARY ANALYSIS  <b>Presenter: Paul Richardson, USA</b></p> <p>ORAL IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (IRD) VERSUS PLACEBO-RD FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANT: THE MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TOURMALINE MM2 TRIAL  <b>Presenter: Thierry Facon, France</b></p>
<b>12:30-14:00</b>	<p><b>Industry sponsored symposium (Sanofi)</b></p>



## COMy Online 2020 Scientific Program

<b>14:00-15:30</b>	<b>Session 6: Therapy of relapsed/refractory myeloma</b>
	Anti-CD38-based combinations <b>Saad Usmani, USA</b>
	IMiDs: past, present and future <b>Xavier Leleu, France</b>
	Round table discussion <b>Saad Usmani, USA, Xavier Leleu, France, Enrique M. Ocio, Spain, Cyril Touzeau, France, Shaji Kumar, USA</b>
<b>15:30-17:00</b>	<b>Session 7: Immunotherapy for myeloma</b>
	Bispecific antibodies <b>Luciano Costa, USA</b>
	CAR-T Cells <b>Noopur Raje, USA</b>
	Round table discussion <b>Luciano Costa, USA, Noopur Raje, USA, Salomon Manier, France, Sagar Lonial, USA</b>
<b>17:00-18:00</b>	<b>Session 8: Plenary lecture</b>
	Multiple Myeloma Excellence Award ceremony Presented to: <b>Saad Usmani, USA</b> by Congress Co-Chairs
	Multiple Myeloma Excellence Award lecture <b>Saad Usmani, USA</b>
	Management of AL amyloidosis: what's new? <b>Giampaolo Merlini, Italy</b>
	Round table discussion <b>Giampaolo Merlini, Italy</b>
<b>18:00-19:30</b>	<b>Industry sponsored symposium (Adaptive Biotechnologies)</b>

*We wish to thank the following for their support of the COMy program by unrestricted grant: Celgene and ProMedico for their support of the program overall, Janssen for their support of Session 2 and Oncopeptides for their support of Session 6*